Development of the innovative drugs and therapies based on new drug targets and mode of actions
Angalbio's innovative drug development projects are based on the target deconvolution and verification technology platform developed by the R&D team, as well as the new drug targets and mode of actions discovered based on related platforms.
Modern technology combined with TCM practical experience and natural resources
Using world-class modern technology to discover the mode of actions of Traditional Chinese herbal medicine, combined with modern technologies such as AI-aided drug screening and cell engineering, to develop the natural compound based innovative drugs and therapies for unmet medical needs.
Main focus areas
Based on the new drug targets and mode of action discovered by the R&D team, Angalbio's R&D platform mainly focuses on developing the innovative drugs and therapies for the following disease areas, i.e. cancer, infectious, metabolic and neurodegenerative diseases.
We have licensed an unbiased forward genetic screening approach from JLP Health that uncovers the molecular on- and off-target space of drug candidates at unprecedented amino acid resolution. We use chemical mutagenesis combined with next generation sequencing and advanced bioinformatics algorithms to identify specific amino acid sites that are critical for the drug’s mode of action. Through saturating screens we are able to map the compound-target binding interface.